ClinicalTrials.gg
Active, not recruitingNCT02717624Updated Jul 14, 2026

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

A Phase 1 interventional study of Acalabrutinib in combination with BR and Acalabrutinib in combination with VR in Mantle Cell Lymphoma (MCL), sponsored by Acerta Pharma BV. Active, not recruiting at 15 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell — 5 open to participants now, 20 under way, 1 of them phase 3. acalabrutinib · Lymphoma, Mantle-Cell.

Enrollment
9th of 26
72 · median 49
Started
2016
with 1 other
Phase 1
3 of 26
none open now
Primary completion
2022-06
later than 1 of 19 live
Registered
3rd of 26
by date
Lead sponsor
5 of 26
Acerta Pharma BV

Among the 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell, this one is the 9th largest by enrollment, is one of 2 that started in 2016, is one of 3 in phase 1, reaches primary completion later than 1 of the 19 other live ones, and was the 3rd registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

5 of the 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About acalabrutinib

acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell Lymphoma

Read the detailed description

This is a multicenter, open-label Phase 1b study to assess the safety and efficacy of acalabrutinib when administered concomitantly with bendamustine and rituximab in subjects with treatment naive or relapse refractory mantle cell lymphoma (Part 1), or when administered concomitantly with venetoclax and rituximab in subjects with treatment naive mantle cell lymphoma (Part 2).

03

Conditions studied

  • Mantle Cell Lymphoma (MCL)

Keywords

  • Bruton Tyrosine Kinase Inhibitor
  • BTK
  • Mantle Cell Lymphoma
  • MCL
  • Acalabrutinib
  • ACE-LY-106
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ≥ 18 years of age.
  • confirmed MCL.
  • (ECOG) performance status of ≤ 2.
  • Agreement to use highly effective forms of during the study and for 2 days after the last dose of acalabrutinib, 30 days after the last dose of venetoclax, or 12 months after the last dose of rituximab, whichever is longest.
  • Treatment Naive MCL patients requiring treatment with no exposure to prior therapies.

Exclusion criteria

Exclusion Criteria:

  • Significant cardiovascular disease such as uncontrolled or untreated symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the Functional Classification.Exception: Subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll on study
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass
  • Uncontrolled active systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment), or intravenous anti-infective treatment within 2 weeks before first dose of study drug
  • Breastfeeding or pregnant
  • Concurrent participation in another therapeutic clinical trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Part 1: Acalabrutinib+BR in TN patients

    Part 1: Acalabrutinib in combination with drugs bendamustine and rituximab (BR) in treatment naive patients

    Drug: Acalabrutinib in combination with BR

  • Experimental
    Part 1: Acalabrutinib+BR in RR patients

    Part 1: Acalabrutinib in combination with bendamustine and rituximab (BR) in relapse refractory patients

    Drug: Acalabrutinib in combination with BR

  • Experimental
    Part 2: Acalabrutinib+VR in TN patients

    Part 2: Acalabrutinib in combination with venetoclax and rituximab (VR) in treatment naive patients

    Drug: Acalabrutinib in combination with VR

Interventions

  • DrugAcalabrutinib in combination with BR

    Drug page: Acalabrutinib

    Also known as: Acalabrutinib + BR

  • DrugAcalabrutinib in combination with VR

    Drug page: Acalabrutinib

    Also known as: Acalabrutinib + VR

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events (AEs) as assessed by CTCAE v4.03

    Number of participants who had experienced at least one treatment emergent AE

    Time frame: From first dose of study drug to within 30 days of last dose of study drug

07

Study locations

15 sites
  • Research Site
    Louisville, Kentucky 40207, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Hackensack, New Jersey 07601, United States
  • Research Site
    Morristown, New Jersey 07960, United States
  • Research Site
    Lake Success, New York 11042, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Seattle, Washington 98109, United States
  • Research Site
    Seattle, Washington 98122, United States
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Krakow, 30-510, Poland
  • Research Site
    Lodz, 93-510, Poland
  • Research Site
    Olsztyn, 10-228, Poland
  • Research Site
    Warsaw, 02-106, Poland
08

References and documents

Publications

  • Wang M, Robak T, Maddocks KJ, Phillips T, Smith SD, Gallinson D, Calvo R, Wun CC, Munugalavadla V, Jurczak W. Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis. Blood Adv. 2024 Sep 10;8(17):4539-4548. doi: 10.1182/bloodadvances.2023012424. PubMed 38781315 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Jun 2022, 73 months.

Of 55 industry-sponsored phase 1 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 71. This study's 73 months is above that.

Counting every sponsor, half of 128 studies reached it within 61 months; a quarter within 36 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2016
First posted
Mar 24, 2016
StartActual
Apr 20, 2016
Primary completionActual
Jun 15, 2022
CompletionEst.
Aug 20, 2027
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02717624
Lead sponsor
Acerta Pharma BV
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Mar 24, 2016
Start date
Apr 20, 2016
Primary completion
Jun 15, 2022
Completion
Aug 20, 2027 (estimated)
Last update
Jul 14, 2026

Study contacts

Acerta Clinical Trials
study director · 1-888-292-9613; acertamc@dlss.com

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion